Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer: The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial

IMPORTANCE: The role of epidermal growth factor receptor (EGFR) inhibition in chemoradiation strategies in the nonoperative treatment of patients with esophageal cancer remains uncertain. OBJECTIVE: To evaluate the benefit of cetuximab added to concurrent chemoradiation therapy for patients undergoi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JAMA Oncol
Autors principals: Suntharalingam, Mohan, Winter, Kathryn, Ilson, David, Dicker, Adam P., Kachnic, Lisa, Konski, André, Chakravarthy, A. Bapsi, Anker, Christopher J., Thakrar, Harish, Horiba, Naomi, Dubey, Ajay, Greenberger, Joel S., Raben, Adam, Giguere, Jeffrey, Roof, Kevin, Videtic, Gregory, Pollock, Jondavid, Safran, Howard, Crane, Christopher H.
Format: Artigo
Idioma:Inglês
Publicat: American Medical Association 2017
Matèries:
Original Investigation
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5710193/
https://ncbi.nlm.nih.gov/pubmed/28687830
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2017.1598
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars